Allarity Therapeutics, Inc. (ALLR) News
Follow Allarity Therapeutics, Inc. (ALLR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Bradsaúde’s Atlântica to Take 49.9% Stake in Oncology Venture With Fleury
MNA | Nov 10, 2026, 09:20 PM UTC
L
Allarity Therapeutics expands in-house lab to add proteomics and cell line research
Allarity Therapeutics expanded its in-house medical laboratory to include proteomics and cell line research to support stenoparib development.Key Highlights:Original SEC Filing: Allarity Therapeutics, Inc. [ ALLR ] - 8-K
REGULATION | Sep 29, 2026, 12:03 PM UTC
L
Allarity Therapeutics, Inc. (ALLR) Adds Proteomics and Cell Line Capabilities
Allarity Therapeutics expanded its lab to include proteomics and cell line research to support stenoparib studies and external services, saying this will not affect its current cash runway.Material DetailsContext by AI A
NEWS | Sep 28, 2026, 12:01 PM UTC
L
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib- New proteomics and cell line capabilities will broaden Allarity’s research capabilities to enable external partnershipsTARPON S
NEWS | Sep 28, 2026, 12:01 PM UTC
H
Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
Shares of Lobo Technologies Ltd (NASDAQ: LOBO ) rose sharply in pre-market trading after the company reported a year-over-year increase in H1 financial results. Lobo EV Technologies posted a H1 loss of 7 cents per share,
LIVE | Sep 21, 2026, 09:01 AM UTC
L
Allarity Therapeutics wins Japanese patent for stenoparib diagnostic
The company said Japan's patent office granted a key patent for its stenoparib-specific DRP® companion diagnostic, extending protection in Japan into 2039.
EQUITY | Sep 16, 2026, 12:03 PM UTC
L
Allarity Therapeutics, Inc. Secures Japan Patent for Stenoparib DRP to 2039
Allarity Therapeutics received a Japanese patent for its stenoparib-specific DRP companion diagnostic, with protection into 2039. The patent covers methods to predict benefit from stenoparib and to select patients using
NEWS | Sep 15, 2026, 12:03 PM UTC
L
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
TARPON SPRINGS, Fla., September 15, 2026 — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) NASDAQ:ALLR, a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiat
NEWS | Sep 15, 2026, 12:03 PM UTC
L
ALLR - Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
ALLR - Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
NEWS | Sep 15, 2026, 12:00 PM UTC
L
Allarity Therapeutics reports Q2 2026 results; Stenoparib Phase 3-ready campaign completed
Allarity Therapeutics reports second quarter 2026 results and states it has completed the Phase 3-ready Stenoparib manufacturing campaign.
EARNINGS | Aug 14, 2026, 12:00 PM UTC
L
Allarity Therapeutics Receives U.S. Patent And Trademark Office Patent For Its Drug Response Predictor Companion Diagnostic
Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR ), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor
EQUITY | Jun 30, 2026, 12:04 PM UTC
M
Healthcare Stocks Move
Gainers Catheter Precision (AMEX: VTAK ) shares rose 78.2% to $1.55 during Monday's after-market session. The company's market cap stands at $2.2 million. Allarity Therapeutics (NASDAQ: ALLR ) stock increased by 8.08% to
EQUITY | Jun 22, 2026, 09:10 PM UTC